Dermatology Times

📹 Explore key benchmarks, emerging trends, personalized medicine approaches, long-term safety considerations, and the integration of novel therapies in the management of atopic dermatitis in our informative Expert Perspectives series. Each interview provides valuable insights into navigating the heterogeneity of atopic dermatitis presentations, selecting appropriate treatment plans tailored to individual patient needs, and incorporating the latest guidelines to help enhance patient care. View the full series here: https://ow.ly/szkm50SyhN0

🚨BREAKING: The US FDA has approved Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) supplemental new drug application for #roflumilast (Zoryve) cream 0.15% for the treatment of patients aged 6 years and older with mild to moderate #atopicdermatitis. “What is really unique about the profile of Zoryve cream is that it works quickly, but it’s also appropriate for long-term treatment. Oftentimes, we would have to go to 2 different therapies in order to address these different parts of the treatment. For an atopic dermatitis patient, it’s important that you work quickly because this is a disease that has a lot of itching and symptoms that need to be relieved,” said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis, in an interview with Dermatology Times. https://lnkd.in/g-5Qg2CG

📰 FROM OUR PUBLICATION: In light of Valisure's findings of benzene in #benzoylperoxide products, some patients may be looking for alternatives to BPO, questioning its safety. What should clinicians tell their patients? Read more: https://lnkd.in/gzRu9VT5

📰 FROM OUR PUBLICATION: Adewole Adamson, MD, MPP, addresses the Environmental Working Group's recent report highlighting potential shortcomings in sunscreens available in the US market. He delves into what clinicians should know about it and what they should tell their patients. 🖇READ MORE: https://lnkd.in/gb_WeTrG

📰 FROM OUR PUBLICATION: Our Summer Editor in Chief, Shanna Miranti, MPAS, PA-C, reflects on her 22+ years in dermatology, sharing lessons learned from her parents and mentors. "Be happy, be humble, and be brilliant," she writes. 🖇READ MORE: https://lnkd.in/ggCCBYtf

🧬 REGULATORY UPDATE: Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) today provided an update on the delayed status of the FDA’s approval of #roflumilast cream 0.15% for the treatment of patients aged 6 years and older with mild to moderate #atopicdermatitis. The FDA is working to finalize the action letter and did not indicate it will need to extend the Prescription Drug User Fee Act goal date of July 7, 2024. https://lnkd.in/gT7zT46V

🌟 EXPERT INSIGHTS: Mona Shahriari, MD, FAAD, shares pearls on patient referrals to other specialties, including collaborative care, early intervention, and telemedicine. Shahriari discusses referring patients to rheumatologists, prioritizing cross-discipline collaboration, and the importance of improving patient outcomes. 🖇READ MORE: https://lnkd.in/gmsmW6Ur

🌟 On July 8, 2024, the ILDS and IDS will inaugurate the first official World Skin Health Day. As a key partner, CeraVe will play a significant role in this global initiative by spotlighting new survey data and amplifying dermatology changemakers. https://lnkd.in/gRnnDaba

🗞 IN THE NEWS: Review our recap of the latest news and headlines in dermatology from last week, including the appointment of the Canadian Dermatology Association's new president, a program aimed at supporting diverse, aspiring dermatologists, and more. https://lnkd.in/g6hGCchP

🗓 WEEKLY ROUNDUP: Review our recap of dermatology news and coverage from last week, including news about the FDA's approval of biosimilar #ustekinumab-ttwe, addressing acne scarring concerns, and more. https://lnkd.in/g3qyUn8j